London-based Orakl Oncology secures $34 million to advance AI-powered virtual patient platform for cancer drug testing
Orakl Oncology, a UK‑based healthtech startup, secured $34 million in funding to advance its AI platform that generates virtual patients for cancer‑drug testing, aiming to speed up drug development and reduce reliance on animal studies.